Novelties in the field of anti-infectives in 1998

Clinical Infectious Diseases

Volumn 29, Issue 3, 1999, Pages 632-658

  Bryskier, André ^a  

^a SANOFI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

6 (1 HYDROXYETHYL) 4 METHYL 7 OXO 3 [1 (2 THIAZOLIN 2 YL) 3 AZETIDINYL] 1 AZABICYCLO[3.2.0]HEPT 2 ENE 2 CARBOXYLIC ACID PIVALOYLOXYMETHYL ESTER; 7 (3 AMINO 4 FLUOROMETHYL 1 PYRROLIDINYL) 1 CYCLOPROPYL 6 FLUORO 1,4 DIHYDRO 8 METHOXY 4 OXO 3 QUINOLINECARBOXYLIC ACID; A 165753; A 170568; AMOXICILLIN; AMPHOTERICIN B; ANTIFUNGAL AGENT; ANTIINFECTIVE AGENT; CARBACEPHEM DERIVATIVE; CARBAPENEM DERIVATIVE; CEFTAZIDIME; CIPROFLOXACIN; FK 483; FLUCONAZOLE; FROPENEM; GREPAFLOXACIN; ITRACONAZOLE; LEVOFLOXACIN; ME 1209; PYRIDONE DERIVATIVE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RWJ 54418; SITAFLOXACIN; SPARFLOXACIN; TEICOPLANIN; TEMAFLOXACIN; TIGECYCLINE; TROVAFLOXACIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; Y 34867;

ANTIMICROBIAL THERAPY; AREA UNDER THE CURVE; CARDIOTOXICITY; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG HALF LIFE; DRUG STRUCTURE; GRAM NEGATIVE INFECTION; HUMAN; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; PHOTOTOXICITY; PRIORITY JOURNAL; REVIEW; STREPTOCOCCUS INFECTION;

EID: 0032871443     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/598646     Document Type: Review

References (142)

1. Bryskier A. Novelties in the field of anti-infectives in 1997. Clin Infect Dis 1998;27:865-83.
2. Kelly LM, Jacobs MR, Appelbaum PC. Anti-pneumococcal activity of SB 265805 (LB 20304a), a new broad spectrum quinolone, compared with nine compounds by MIC [abstract no F 087]. In: Program and abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1998:254.
3. Hori R, Takahata M, Shimakura M, et al. Efficacy of T 3811 ME, a novel des-F(6)-quinolone, against experimental meningitis in rabbits caused by penicillin-resistant S. pneumoniae [abstract no F 078]. In: Program and abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1998:252.
4. Furuhata K, Fukuda H, Shimamoto A, et al. Pharmacological evaluation of T 3811 ME: toxicity on articular chondrocytes in vitro [abstract no F 077]. In: Program and abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1998:252.
5. Orero A, Canton E, Velert M, Gobernado M. Uptake of grepafloxacin into polymorphonuclear leukocytes: influence of anti-inflammatory drugs [abstract no A 115]. In: Program and abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1998:36.
6. Takahashi Y, Fujii A, Sakamoto K, et al. Uptake and intracellular activity of HSR 903, a new quinolone, in human polymorphonuclear leukocytes [abstract no F 082) In: Program and abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC: American Society for Microbiology, 1998:253.
7. Tanaka M, Namba K, Chiba M, Sato K. DC 756, a new methoxyquinolone: in vitro antibacterial activity against clinical isolates [abstract no F 074]. In: Program and abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1998:251.
8. Takahashi H, Kawakami K, Sugita K, et al. DC 756, a new methoxyquinolone: synthesis and in vitro activity of 7-[(3-amino-4-substituted)pyrrolidin-1-yl] derivatives [abstract no F 073]. In: Program and abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1998.251.
9. Yabe K, Murakami Y, Yamamoto W, et al. DC 756, a new methoxyquinolone: toxicological and pharmacokinetic evaluation [abstract no F 072]. In: Program and abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1998:251.
10. Sakurai N, Hirayama F, Sano M, et al. Synthesis and anti-H. pylori activity of Y-34867, a new 7-morpholinoquinolone [abstract no F 085]. In: Program and abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1998:254.
11. Van Zwet AA, Vandenbrouke-Grauls CMJE, Thijs JC, Van der Wonden EJ, Gerrits MH, Kusters JG. Stable amoxicillin resistance in H. pylori, Lancet 1998;352:1595.
12. Dekker KA, Inagaki T, Gootz TD, et al. New quinolone compounds from Pseudonocardia sp with selective and potent anti-H. pylori activity: taxonomy of producing strain, fermentation, isolation, structural elucidation and biological activities. J Antibiotics 1998;51:145-52.
13. Armiger YI., Chu DTW, Fung AKL, et al. The discovery of A 165,753 and A 170,568, two potent broad spectrum antimicrobial agents [abstract no F 86]. In: Program and abstracts of 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC: American Society for Microbiology, 1998:254.
14. Bryskier A, Agouridas C, Chantot JF. In: Zinner SH, Young LS, Acar JF, Neu HC: Ketolides: new semisynthetic 14-membered-ring macrolides in expanding indications for the new macrolides, azalides and streptogramm. New York: Marcel Dekker, 1998:39-50.
15. Lenfant B, Sultan E, Wable C, Pascual MH, Meyer BH. Pharmacokinetits of 800 mg once-daily oral dosing of the ketolide HMR 3647 in healthy young volunteers [abstract no A 49]. In: Program and abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1998:16.
16. Anderson M, Bergeron J, Blair K, et al. In vitro and in vivo activity and mechanism of action of CP 279,107, a C4″-bisaryl erythromycylamine derivative with potent activity against macrolide-resistant streptococci [abstract no F 128]. In: Program and abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1998:264.
17. Girard D, Mathieu HW, Girard AE, et al. Pharmacokinetics and pharmacodynamics of CP 544,377, a new crythromycylamine C4″ carbamate, in murine pneumococcal pulmonary infections [abstract no F 120]. In: Program and abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1998:262.
18. Girard D, Mathieu HW, Girard AE, et al. In vivo oral efficacy of CP 544,372, a new crythromycylamine C4″ carbamate against macrolide-resistant pneumococci and H. influenzae [abstract no F 121]. In: Program and abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC; American Society for Microbiology, 1998:263.
19. Su WG, Smyth KT, Rainvilie JP, et al. Novel crythromycylamine C-4″-carbamate antibacterial agents: synthesis and biological evaluation resulting in discovery of CP 544,372 [abstract no F 122], In: Program and abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1998:263.
20. Wu YJ, Won R Jr, Darkin D, et al. Synthesis and in vitro activity of novel C-4″ carbamates of 14- and 15-membered macrolides [abstract no F 123]. In: Program and abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1998:263.
21. 90 studies and killing kinetics against key respiratory tract pathogens [abstract no F 124]. In: Program and abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1998:264.
22. Fernandes PB, Baker WR, Freiberg LA, Hardy DJ, McDonald EJ. New macrolides active against S. pyogenes with inducible or constitutive type of macrolide-lincosamide streptogramin B resistance. Antimicrob Agent Chemother 1989;33:78-81.
23. Pacev MS, Dirlam JP, Geldart RW, et al. Novel erythromycins from a recombinant Saccharopolyspora crythrea strain NRRL 2338 plGl. I. Fermentation, isolation and biological activity. J Antibiotics 1999;51: 1029-34.
24. Poras H, Kunesh G, Barrère JC, Berthaud N, Andremont A. Synthesis and in vitro antibacterial activity of catechol spiramycin conjugate J. Antibiotics 1998;51:788-94.
25. Kurihara KI, Ajito K, Shibahara S, et al. Cladinose analogues of sixteen-membered macrolide antibiotics. VI. Synthesis of metabolically programmed, highly potent analogues of sixteen-membered macrolide antibiotics. J Antibiotics 1998;51:771-85.
26. Norcia LJL, Seibel SB, Kamicker BJ, et al. In vitro microbiological characterisation of novel macrolide CP 163,505 for animal health specific use. J Antibiotics 1998;51:136-44.
27. Bergogne-Bérézin E, Drugeon H, Mignot A. The suppository form of antibiotics administration revisited: improvement of rectal bioavailability of macrolides. Update of spiramycin [abstract no A 101]. In: Program and abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1998:32.
28. Phan LJ, Or YS, Chan Y, et al. 2-Substituted tricyclic ketolides: new antibacterial macrolides. Synthesis and biological activity [abstract no F 127]. In: Program and abstracts of the 38th Interseience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1998:264.
29. Ma Z, Or YS, Clark R, et al. Synthesis and antibacterial activity of 6-O-substituted ketolides [abstract no F 126]. In: Program and abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC; American Society for Microbiology, 1998:264.
30. Clark RF, Or YS, Ma Z, et al. Novel 6-O-substituted erythromycin A derivatives: synthesis and antibacterial activity [abstract no F 125]. In: Program and abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1998:264.
31. Mikels SM, Lenoy EB, Allen W, Compton S, Weiss WJ. Therapeutic efficacy of GAR 936 (GAR), a novel glycylcycline, in murine infections [abstract no F 135]. In: Program and abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC: American Society for Microbiology, 1998:266.
32. Weiss WJ, Murphy TM, Mikels SM, Clegg J. GAR 936, a novel glycylcycline, in the treatment of experimental endocarditis [abstract no F 136]. In: Program and abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC: American Society for Microbiology, 1998:267.
33. Van Ogstrop ML, Andes D, Graig WA, Weiss WJ, Vesga O, In vivo pharmacodynamic activity of two glycylcyclines (GAR 936 and WAY 153289) against various gram-positive and gram-negative bacteria [abstract no F 134]. In: Program and abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1998:266.
34. Van Ogstrop ML, Andes D, Graig WA, Vesga O. In vivo activity of two glycylcyclines (GAR 936 and WAY 152288) against tetracycline-sensitive and -resistant bacteria [abstract F 133]. In: Program and abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1998:266.
35. 14CPNU 100,766 to healthy volunteers [abstract no A 53]. In: Program and abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC; American Society for Microbiology, 1998:17.
36. Brier ME, Stalkers DJ, Aronoff GR, et al. Pharmacokinetics of linezolid in subjects with varying degrees of renal function and on dialysis [abstract no A 54]. In: Program and abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1998:17.
37. Swaney SM, Shinabarger D, Schaadt D, Bock JH, Slightom JL, Zurenko GE. Oxazolidinone resistance is associated with a mutation in the peptidyltransferase region of 23SrRNA [abstract no C 104]. In:Program and abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1998:98.
38. Hutchinson DK, Barbachyn MR, Hester JB, et al. Synthesis and antibacterial activity of azolylphenyloxazolidinones having nitrogen-bound five membered heterocyclic rings [abstract no F 137]. In: Program and abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1998:267.
39. Genin MJ, Allwine DA, Hutchinson DJ, et al. Substituent effect on the antibacterial activity of novel highly potent nitrogen-bound azolyl phenyloxazolidinones [abstract no F 138]. In: Program and abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1998:267.
40. Gadwood RC, Walker EA, Thomasco LM, et al. Synthesis and antibacterial activity of azolylphenyl oxazolidinones having carbon-bound 1,3 thiazolyl rings [abstract no F 139]. In: Program and abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC: American Society for Microbiology, 1998: 267.
41. Enderman R, Bartel S, Guamieri W, et al. Synthesis and antibacterial activity of novel heteroaryl oxazolidinones, III: activities against clinically important gram-positive pathogens [abstract no 129]. In: Program and abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1998:265.
42. Wild H, Bartel S, Endermann R, et al. Synthesis and antibacterial activity of novel heteroaryl oxazolidinone. II: replacements of the N-acetyl moiety in several series [abstract no F 130]. In: Program and abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1998:265.
43. Bartel B, Endermann R, Guarnieri W, et al. Synthesis and antibacterial activity of novel heteroaryl oxazolidinones. I: benzoxazolone and benzothiazolone oxazolidinones [abstract no 131]. In: Program and abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1998:265.
44. Bryskier A, Aszodi J, Chantot JF. Parenteral cephalosporin classification. Expert Opin Invest Drugs 1994;3:145-71.
45. Bryskier A. Novelties in the field of parenteral cephem antibacterials since 1993. Expert Opin Invest Drugs 1997;6:305-20.
46. Temansky RJ, Darheim SE, Dike AJ, et al. Discovery and structure activity relationships of a series of 1-carba-I-dethiacephems exhibiting methicillin-resistant Staphylococcus aureus activity. J Med Chem 1993;36:1971-6.
47. Choi KL, Cha JH, Pae AN, Cho YS, Chang MH, Koh HY. Studies on novel 3-isoxazolylvinyl cephalosporins: I - synthesis and biological activity of 7-[2-(2-aminothiazol-4-yl)-2-(alkoxy) aminoaccetamido] derivatives. J Antibiotics 1998;51:1117-21.
48. Hecker SJ, Cho IS, Glinka TW, et al. Discovery of MC 02,331, a new cephalosporin exhibiting potent activity against methicillin-resistant S. aureus. J Antibiotics 1998;51:722-34.
49. Kim OK, Hydynia TW, Mafiskella JD, Ueda Y, Bronson JJ, Mansuri MM. Synthesis and structure-activity relationship of C-3 quaternary ammonium cephalosporins exhibiting anti-MRSA activities. Bioorg Med Chem Lett 1997;7:2743-58.
50. Atsumi K, Iwamatsu K, Shibahara S, Shiokawa S, Tomura A (Meiji Seika Kaishu Ltd). New 2-thiazolylvinyl cephalosporin compounds are antibacterials active against, e.g., methicillin-resistant S. aureus. WO 9509171 April;6:1995.
51. Nguyen T, Liu E, Malouin F, Blais J, Chamberland S. MC 02,479/ RWJ54,428: binding to multiple PBPs may be associated with low frequency of resistance [abstract no F 017]. In: Program and abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1998:237.
52. Blais J, Hoang MK, Chamberland S, Kreiswirth B. Survey of clinical isolates of methicillin-resistant S. aureus (MRSA) for susceptibility to MC 02,479/RWJ 54,428, a new cephalosporin [abstract no F 015]. In: Program and abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1998:236.
53. Hebeisen P, Angehm P, Heinze-Krauss I, et al. Synthesis and SAR of pyrrolidinone-3-ylidenmethyl cephems against methicillin-resistant S. aureus [abstract no F 021]. In: Program and abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1998:238.
54. Hebeisen P, Gross G, Heinze-Krauss I, Hubschwerlen C, Schmitt-Hoffmann AH, Theil FP. Synthesis, physicochemical and pharmacokinetic properties of water soluble prodrugs of Ro 63-9141 [abstract no F 026]. In: Program and abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1998:239.
55. Hohl P, Angehrn P, Then RI., Hebeisen P, Heinze-Krauss I. Ro 63-9141, a novel broad-spectrum anti-MRSA pyrrolidinone cephalosporin. Part I: activity against aerobic gram-negatives [abstract no F 023]. In: Program and abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1998:238.
56. Zbinden R, Puenter V, von Graevenitz A. Ro 63-9141, a novel broad-spectrum anti-MRSA pyrrolidinone cephalosporin. Activity against gram-negative non fermenters [abstract no F 019]. In: Program and abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1998:237.
57. Bowker KE, Wootlon M, Holt HA, Mac Gowan AP. In vitro activity of Ro 63-9141, a novel broad-spectrum anti-MRSA pyrrolidinone cephalosporin: activity against clinically significant anacrobes [abstract no F 020]. In: Program and abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1998:238.
58. Hohl P, Angehrn P, Then RL, Hebeisen P, Heinze-Krausse I. Ro 63-9141, a novel broad-spectrum anti-MRSA pyrrolidinone cephalosporin. Part II: activity against gram-positives including MRSA [abstract no F 024]. In: Program and abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1998:239.
59. Page M, Bur D, Hebeisen P, et al. Inhibition of the penicillin-binding proteins of methicillin-resistant Staphylococcus aureus by pyrrolidinone-3-ylidenemethyl cephems [abstract F 022]. In: Program and abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1998:238.
60. Theil FP, Schönlein K, Schenk P, Schmitt-Hoffmann A. Pharmacokinetics of the cephalosporin Ro 63-9141 in five animal species. Extrapolation to man [abstract no F 025]. In: Program and abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1998:239.
61. Heinze-Krauss I, Angehm P, Guerry P, et al. Synthesis and structure-activity relationship of (lactamylvinyl) cephalosporins exhibiting activity against staphylococci, pneumococci and enterococci. J Med Chem 1996;39:1864-71.
62. Atsumi K, Iwamatsu K, Umemura E, et al, CP 6679, a new injectable cephalosporin: I. Synthesis and structure-activity relationships [abstract no F-43]. In: Program and abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1995:120.
63. Tamura A, Miyata A, Ishii T, et al. CP 6679, a new injectable cephalosporin: in vitro antibacterial activity [abstract no F-44]. In: Program and abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Miciobiology, 1995:120.
64. Tamuran A, Ishii T, Mitomi N, et al. CP 6679, a new injectable cephalosporin: III In vivo antibacterial activity [abstract no F-45]. In: Program and abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1995:120.
65. Ida T, Kurazono M, Yoshida T, et al. ME 1209 (CP 6679), a new parenteral cephalosporin. I: in vitro and in vivo activity against MRSA [abstract no F 012]. In: Program and abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1998:235.
66. Yoshida T, Ida T, Karazono M, et al. ME 1209 (CP 6679), a new parenteral cephalosporin. II: in vitro and in vivo activity against P. aerugmosa [abstract no F 011]. In: Program and abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1998:236.
67. Hoeliman DB, Jacobs MR, Appelbaum PC. Antipneumococcal activity of MEN 10,700 (a new broad-spectrum penem) compared to 8 other agents by MIC [abstract no F-1]. In: Program and abstracts of the 38th interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC: American Society for Microbiology, 1998:233.
68. Kim JH, Lee JS, Puyn DK, Lec CH. A new carbapenem. I: synthesis and structure-activity relationship of 1 β-methyl-2-(α-functionalized) carbapenems [abstract no F 046]. In: Program and abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1998:244.
69. Park SY, Kim DY, Kim KH, Kim JH, Jeon BC, Lee CH. KR 21,056, a new carbapenem. IV: an orally absorbed prodrug ester of KR 21,012 [abstract no F 045). In: Program and abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1998,244.
70. Park SY, Park SH, Kim DY, Kim JH, Kim MH, Lee CH. KR 21,012, a new carbapenem. II: in vitro and in vivo antibacterial activity [abstract no F 047]. In: Program and abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1998:244.
71. Kim EI, Kim JH, Jeong HJ, Kim BJ, Song JS, Lee CH. KR 21,012, a new carbapenem. III: pharmacokinetics and safety profile [abstract no F 044]. In: Program and abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1998:244.
72. Abe T, Hayashi K, Mihira A, et al. L 084, a new oral carbapenem: synthesis and structure-activity relationships of C-2 substituted 1β-methylcarbapenems [abstract no F 64]. In: Program and abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1998: 249.
73. Nishino T, Yoshida M, Otsuki M. L 084, a new oral carbapenem: in vitro activity [abstract no F 67]; In: Program and abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1998:250.
74. Miyazaki S, Hosoyama T, Furuya N, et al. L 084, a new oral carbapenem: in vitro and in vivo antibacterial activity [abstract no F 69]. In: Program and abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1998:250.
75. Inone M, Kuga A, Sato Y, Okamoto R, L 084, a new oral carbapenem: in vitro antibacterial activity against clinical isolates of β-lactamase producers [abstract no F 63]. In: Program and abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1998:249.
76. Kato N, Kato H, Tanaka K. Watanabe K. L 084, a new oral carbapenem: in vitro activity against anaerobic bacteria [abstract no F 70]. In: Program and abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1998:249.
77. Kawamoto L. 1-β-methylcarbapenem antibiotics. Drugs of the Future 1998;23:181-9.
78. Wilkening RR, Ratcliffe RW, Wildonger KJ, et al. Synthesis and evaluation on anti-MRSA 1-β-methyl-2-(naphtosultamyl)methyl carbapenems. Discovery of I. 786,392 [abstract no F 032]. In: Program and abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC: American Society for Microbiology, 1998:240.
79. 2a-binding, anti-MRSA, 1,8-naphtosultamyl pharmacophore [abstract no F 033]. In: Program and abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1998: 241.
80. Pelak BA, Gerckens LS, Sinclair PJ, Scott PM, Suber D, Rosen H. Expanded in vitro antibacterial profile of L 786,392, a new carbapenem [abstract no F 042]. In: Program and abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC: American Society for Microbiology, 1998:243.
81. Dorso KL, Kohler J, Kropp H, Rosen H, Silver LL. In vitro anti-enterococcal activity of L 786,392, alone and in combination with other antibacterial agents [abstract no F 028]. In: Program and abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC: American Society for Microbiology, 1998:240.
82. Huber J, Dorso KL, Kohler J, Kropp H, Rosen H, Silver LL. Antistaphylococcal activity of the MRS-active carbapenem L 786,392 [abstract no F 30]. In: Program and abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC: American Society for Microbiology, 1998:240
83. Hammond GG, Epsters T, Toney JH, L 786,392, a novel carbapenem with improved binding to low-affinity penicillin-binding proteins of methicillin-rcsislant S. aureus and E. hirac [abstract no F 041]. In: Program and abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1998:243.
84. Jackson JJ, Gill CJ, Kropp H, Rosen H. Protective efficacy of a novel carbapenem (L 786,392) against vancomycin-resistant E. faecium CL 5053 in a localized (thigh) mouse infection model [abstract no F 039]. In: Program and abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1998:242.
85. Gill CJ, Jackson JJ, Sundelof JG, et al. In vivo activity of L 786,392, a novel long-acting carbapenem antibiotic, in mouse models of localized and systemic S. aureus infections [abstract no F 040]. In: Program and abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1998:243.
86. May WJ, Sundelof JG, Rosen H. In vivo activity of L 786,392 in murine pulmonary and septicemia models of infections with penicillin-resistant S. pneumoniae [abstract no F 038]. In: Program and abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1998:242.
87. Sundelof JG, Pelak BA, Hajdu R. et al. Pharmacokinetics and pharmacodynamics of L 786,392 in mice and rats [abstract no F 037]. In: Program and abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1998:242.
88. Hajdu R, Sundelof JG, Thompson R, Gill CJ, Kropp H, Rosen H. Preliminary metabolism and disposition of L 786,392 in the rhesus monkey and chimpanzee [abstract no F 36]. In: Program and abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1998:242.
89. Sundelof JG, Hajdu R, Gill CJ, Thompson R, Rosen H, Kropp H. Pharmacokinetics of L-1749,345, a long acting carbapenem antibiotic in primates. Antimicrob Agent Chemother 1997;41:1743-8.
90. Hajdu R, Lankas G, Sundelof J, et al. Preliminary tolerability studies of the novel MRS-active naphtylsultamyl-carbapcnem L 786,392 in mice, rats, rabbits, dogs and rhesus macaques [abstract no F 35]. In: Program and abstracts of the 38th Interference Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1998:241.
91. Shimizu A, Imamura H, Sato H, et al. J 111,225, a novel trans-7,5-disubstituted pyrrolidylthio-1β-methyl carbapenem: synthesis and physicochemical properties [abstract no F 061]. In: Program and abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1998:248.
92. Sato H, Shimizu A, Imamura H, et al. J 114,870 and J 114,871, novel trans-3-5-disobstituted pyrrolidinylthio-1β-methylcarbapenems: synthesis and physicochemical properties [abstract no F 056]. In: Program and abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1998:247.
93. Shimizu A, Sugimoto Y, Sukuraba S, et al. Novel trans-3,5-disubstituted pyrrolidinylthio-1β-methylcarbapenems with potent activity against MRSA and P. aeruginosa [abstract no F 052]. In: Program and abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1998:246.
94. Adachi Y, Nagano R, Shibata K, Kato Y, Hashizume T, Morishima H. In vitro activities of J 111,225, J 114,872 and J 114,871, novel carbapenems having potent activities against MRSA and P. aeruginosa [abstract no F 054]. In: Program and abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1998:246.
95. Shibatu K, Nagano R, Hoshizume T, Morishima H. in vivo efficacy of J 111,225 in mouse experimental infection models including mixed infection with MRSA and P. aeruginosa [abstract no F 057]. In: Program and abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1998:247.
96. Nagano R, Adachi Y, Hashizume T, Morishima H. J 111,225, a novel trans-3,5-disubstituted pyrrolidinylthio 1β-methyl carbapenem; inhibitor of IMP-1 metallo-β-lactamase [abstract no F 055]. In: Program and abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1998:247.
97. Shibata K, Nagano R, Adachi Y, et al. Studies on pharmacokinetics and basic toxicity of novel trans-3,5-disubstituted pyrrolidinylthio-1β-methylcarbapenem [abstract no F 053]. In: Program and abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1998:246.
98. Paternotte I, Burton S, Sonvcaux E, Tulkens PM. Uptake of esters prodrugs of ampicillin (pivampicillin, phtalimidomethylampicillin, S-acetyl-2-thioethylampicillin) in macrophages and PMN with intra-cellular liberation of ampicillin [abstract no F 07]. In. Program and abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC: American Society for Microbiology, 1998:234.
99. Fan HJ, Paternotte J, Vemander M, et al. Estet prodrugs of ampicillin tailed for intracellular accumulation. Bioorg Med Chem Lett 1997;7: 3107-12.
100. Nagao Y, Kumagai T, Kobayashi S, et al. Synthetic approach toward the development of new β-lactamase inhibitors. Heterocycles 1997;46: 193-8.
101. Buynak JD, Rao AS, Adam G, Nidamarthy S, Doppalpudi VR. New β-lactamase inhibitors with broad activity [abstract no F 13]. In: Program and abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC: American Society for Microbiology, 1998:236.
102. Malabarba A, Ciabatti R, Romano G, et al. BI 397: a new developmental semisynthetic glycopeptide antibiotic [abstract no F 107]. In; Program and abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1998:259.
103. Snyder NJ, Cooper RDG, Briggs BS, et al. Enzymatic deacylation of teicoplanin followed by reductive alkylation: synthesis and antibacterial activity of new glycopeptides [abstract no F 110]. In: Program and abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1998:260.
104. Wilkie SC, Letourneau DL, Mullen DL, et al. N-terminal modification of glycopeptide antibiotics: synthesis, antibacterial activity and mechanism of action [abstract no F 115]. In: Program and abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC: American Society for Microbiology, 1998; 261.
105. Fajardo TT Jr, Villahermosa LG, delaCruz EC, Abalos RM, Franzblau SG, Walsh GP. Minocycline in lepromatous leprosy. Intern J Leprosy 1995;63:8-17.
106. Franzblau SG, Deming A, Biswas AN, Robinson SO, Cantrell L. Structure-activity relationships of tetracyclines against M. tuberculosis [abstract no F 197]. In: Program and abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1998:283.
107. Suling WJ, Allen LB, Quenelle DC, Wilson LN, Reynolds RC. Activities of calmodulin antagonists against M. tuberculosis (MTB) in vitro and in vivo [abstract no F 196]. In: Program and abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American
108. Xiong YQ, Yeaman MR, Bayer AS. In vitro microbicidal activity of thrombin-induced platelet microbicidal protein (tPMP) and human neutrophil defensin (HPN-1) on S. aureus (SA) are substantially influenced by pretreatment with antibiotics differing in mechanism of action [abstract no F 169]. In: Program and abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1998:275.
109. Koo SP, Kagan BL, Yeaman MR, Bayer AS. Membrane permeabilization by thrombin-induced platelet microbicidal protein-1 (tPMP-1) is modulated by transmembrane voltage orientation and magnitude [abstract no F 171]. In: Program and abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1998:276.
110. McNicol PJ, Howlett L, Hasham K, Lopez JA, Martin W, West MHP. Cationic peptide antibiotics act as single agents or restore the in vitro activity of conventional antimicrobials against drug-resistant pathogenic micro-organisms [abstract no F 168]. In: Program and abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC: American Society for Microbiology, 1998:275.
111. 21 [abstract no F 172]. In: Program and abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1998:276.
112. Park IY, Park CB, Kim MS, Kim SC, Park IY, Parasm I. a novel antimicrobial peptide derived from histone 1 I2A in the catfish Parasilurus asotus [abstract no F 173]. In: Program and abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1998:276.
113. Krijgsveld J, Zaat SA, Kuijpers AJ, Engbers GH, Feijen J, Dankert J. Thromhocidins, bactericidal proteins from human blood platelets are C-terminal deletion products of CXC-chemokines [abstract no F 179]. In: Program and abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American society for Microbiology, 1998:278.
114. Krijgsveld J, Dankert J, Schmidt M, et al. Recombinantly produced thromhocidins, C-terminal trunction forms of CXC-chemokines CTAR III and NAP-2 are potent bactericidal agents [abstract no F 180]. In: Program and abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC: American Society for Microbiology, 1998:278.
115. Park CB, Yi KS, Kim HS, Kim SC, Structure-activity analysis of buforin II, a 21 residue antimicrobial peptide [abstract no F 181]. In: Program and abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1998:279.
116. Hand CM, Class R. Antimicrobial activity of histone II-1 [abstract no F 182]. In: Program and abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1998:279.
117. Alksne LE, Burgio P, Bradford P, et al. Identification of inhibitors of bacterial secretion by using a secA reporter system [abstract no F 157]. In: Program and abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1998:272.
118. Yuan H, Gallant P, Shen X, Tao J. Bacterial SecA as an antimicrobial target [abstract no F 162]. In: Program and abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1998:273.
119. Chen D, Rosenow C, Trias J, White RJ, Yuan Z. Pathway screening: novel technology for identifying inhibitors of Mur A-F in a single incubation [abstract no F 160]. In: Program and abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1998;273.
120. Rosenow C, Trias J. Mur ligases in S. pneumoniae targets for novel antibiotic development [abstract no F 165]. In: Program and abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1998:274.
121. Hilliard JJ, Licata L, Gloldschmidt R, et al. Multiple mechanisms of action for inhibitors of histidine protein kinase from bactrerial two-component system inhibitors [abstract no F 161]. In: Program and abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC: American Society for Microbiology, 1998:273.
122. Pope MK, Asano RL, Delcardayre SB, Davies JE. Coenzyme A reductase: a novel drug target for staphylococci and enterococci [abstract no 167]. In: Program and abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1998:274.
123. Barlett MS, Loebenberg D, Shaw MM, Durant PJ, Smith JW. Treatment of Pneumocystis carinii with SCII 56,592 in vitro and in vivo [abstract no J 67]. In: Program and abstracts ot the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC: American Society for Microbiology, 1998:470.
124. Al-Abdely H, Najvar J., Bocanegra R Jr, Graybill JR. Activity of SCH 56,592, itraconazole and amphotericin B in experimental murine cerebral phaeohyphomycosis due to Ramichloridium abovoideum (R. makenziei) [abstract no J 068]. In: Program and abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1998:470.
125. Al-Abdely H, Najvar L, Bocanegra R, Graybill JR. SCH 56,592 therapy of experimental murine cerebral phacohyphomycosis due to Cladophialophora bantiana [abstract no J 069]. [n: Program and abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1998:470.
126. Abel MD, Bathini Y, Ha C, et al. Syn 2869, a novel broad-spectrum antifungal triazole: synthesis and structure-activity relationships [abstract no F 148]. In: Program and abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1998:270.
127. Gibb AP, Van den Elzen H, Activity of Syn 2869, fluconazole and itraconazole against 139 consecutive yeast isolates from normally-sterile sites [abstract no F 147]. In: Program and abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1998:270.
128. Salama SH, Gandhi A, Atwal H, et al. Syn 2869, a new potent antifungal triazole for the treatment of systemic and superficial fungal infections: in vitro activity against clinical isolates of yeast and dermatophytes [abstract no F 150]. In: Program and abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1998:270.
129. Johnson EM, Szakly A, Warnock DW, In vitro antifungal activity of Syn 2869 against emerging and less common mold pathogens [abstract no F 153]. In: Program and abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1998:271.
130. Furukawa T, Saito H, Uji T, et al. In vitro activity of Syn 2869, a novel antifungal triazole in murine models of deep mycosis [abstract no F 149]. In: Program and abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC: American Society for Microbiology, 1998:270.
131. Salama SM, Atwal H, Gandhi A, et al. Syn 2869, a new potent antifungal triazole: in vivo efficacy against systemic infections of Torulopsis glabrata and Cryptococcus neoformans in immunosuppressed mice [abstract no F 151]. In: Program and abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1998:271.
132. Kahn JK, Montaseri H, Poglod M, et al. Pharmacokinetics and oral bioavailability of novel triazole derivatives Syn 2869, a potent new antifungal agent, and its comparison with itraconazole [abstract no E 152]. In: Program and abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1998:271.
133. Fujie A, Hori Y, Iwamoto T, et al. FR 901,469, a novel antifungal antibiotic [abstract no F 155]. In: Program and abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1998:272.
134. Ueda S, Tanaka M, Ezaki M, et al. Studies on a novel lipopeptide acylase (FR 179,642 acylase) from Streptomyces sp for production of FR 179,642, a key intermediate of antifungal lipopeptide drug FK 463 [abstract no F 145]. In: Program and abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1998:269.
135. Maki K, Morishita Y, Iguchi Y, et al. In vitro antifungal activity of FK 463, a novel water-soluble echinocandin-like lipopeptide [abstract no F 141]. In: Program and abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1998:268.
136. Matsumoto S, Wakai Y, Maki K, et al. Efficacy of FK 463, a novel water-soluble echinocandin-like lipopeptide in murine models of disseminated candidiasis [abstract no F 142]. In: Program and abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1998:268.
137. Wakai Y, Matsumoto S, Maki K, et al. Efficacy of FK 463, a novel water-soluble echinocandin-like lipopeptide in murine models of pulmonary aspergillosis [abstract no F 143]. In: Program and abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1998:268.
138. Azuma J, Yamamoto I, Ogura M, et al. Phase I study of FK 463, a new antifungal agent, in healthy adult male volunteers [abstract no F 146]. In: Program and abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1998:269.
139. Blondelle SE, Takahashi E, Ostresh JM, Nefzi A, Houghten RA, Novel antifungal compounds derived from heterocyclic positional scanning combinatorial libraries [abstract no F 140]. In: Program and abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1998:268.
140. Manavathu EK, Dimmock JR, Vashishtal SC, Cutright JL, Chandrasekar PH. Proton pumping ATPase-directed fungicidal activity of a novel conjugated styrylketone [abstract no F 159]. In: Program and abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1998:272.
141. Little R, Lim E, Wong E, et al. XMP antifungal peptides demonstrate enhanced selectivity and oral availability [abstract no F 183]. In: Program and abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1998:279.
142. Sein T, Yamagishi H, O'Connell BC, Baum BJ, Walsh TJ. Antifungal activity of histatin 3 and histatin 9 against fluconazole-susceptible and -resistant C. albicans [abstract no F 178]. In: Program and abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1998:278.